UNCY — Unicycive Therapeutics Inc
NASDAQ · Healthcare · Biotechnology
$5.13
+$0.08 (+1.58%)
Unicycive Therapeutics Inc (UNCY) is a biotechnology company listed on NASDAQ. It is led by Shalabh K. Gupta M.D., MPA, based in 1975 West El Camino Real, Mountain View, CA, United States, 94040, with about 21 employees. Unicycive Therapeutics, Inc., a clinical-stage biotechnology company, identifies, develops, and commercializes therapies for the treatment of kidney diseases in the United States. It develops oxylanthanum carbonate, a lanthanum-based phosphate binding agent, which is for the treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI-494, a nicotinamide ester derivative and a selective ATP-sensitive mitochondrial potassium channel activator, which is in Phase I clinical trial for the treatment of acute kidney injury and pre-clinical stage for the treatment of chronic kidney disease. The company was incorporated in 2016 and is headquartered in Mountain View, California.
Net income was -$6.0M. UNCY currently screens at market cap $195.0M.
Use this UNCY page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the UNCY quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the UNCY SEC filings page. Lician reads the product cache first so this HTML stays unique to Unicycive Therapeutics Inc even when a live quote feed is slow.
About Unicycive Therapeutics Inc
Unicycive Therapeutics, Inc., a clinical-stage biotechnology company, identifies, develops, and commercializes therapies for the treatment of kidney diseases in the United States. It develops oxylanthanum carbonate, a lanthanum-based phosphate binding agent, which is for the treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI-494, a nicotinamide ester derivative and a selective ATP-sensitive mitochondrial potassium channel activator, which is in Phase I clinical trial for the treatment of acute kidney injury and pre-clinical stage for the treatment of chronic kidney disease. The company was incorporated in 2016 and is headquartered in Mountain View, California.
UNCY Key Statistics
Market Cap
$195.04M
Volume
415,698
Previous Close
$5.34
Day Range
$5.32 – $5.52
P/B Ratio
5.17
EPS
-$0.56
Revenue
$0.00
Net Income
-$36.73M
Gross Profit
$0.00
Free Cash Flow
$0.00
Revenue Growth
-100.0%
Employees
21
UNCY Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $0.00 | $675.00K | $951.00K | $0.00 |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$36.73M | -$30.54M | -$18.06M | -$10.02M |
| EPS (Diluted) | -$0.56 | -$1.28 | -$1.20 | -$0.86 |
Total Assets
$31.67M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$26.14M
Operating Cash Flow
-$28.57M
Free Cash Flow
$0.00
Unicycive Therapeutics Inc Company Information
- Founder, Chairman, CEO & President
- Shalabh K. Gupta M.D., MPA
- Headquarters
- 1975 West El Camino Real, Mountain View, CA, United States, 94040
- Website
- unicycive.com
- Phone
- 650 351 4495
- IPO / Founded
- 2021-07-12
- Sector
- Healthcare
- Industry
- Biotechnology